CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

@article{Tai2014CRM1II,
  title={CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications},
  author={Y T Tai and Yosef Landesman and Chandrashekhar Waman Acharya and Yolanda De la Calle and Mike Y. Zhong and Michele Cea and Daniel Isaac Tannenbaum and Antonia Cagnetta and Michaela R Reagan and Ammar A. Munshi and William Thomas Senapedis and J-R Saint-Martin and T. Aasish Kashyap and Sharon Shacham and Marcelo Andr{\'e}s Kauffman and Yanyan Gu and Lanxiang Wu and Irene M. Ghobrial and Fenghuang Zhan and Andrew L Kung and Steve A. Schey and Paul Truman Richardson and Nikhil C. Munshi and Kenneth C. Anderson},
  journal={Leukemia},
  year={2014},
  volume={28},
  pages={155-165}
}
The key nuclear export protein CRM1/XPO1 may represent a promising novel therapeutic target in human multiple myeloma (MM). Here we showed that chromosome region maintenance 1 (CRM1) is highly expressed in patients with MM, plasma cell leukemia cells and increased in patient cells resistant to bortezomib treatment. CRM1 expression also correlates with increased lytic bone and shorter survival. Importantly, CRM1 knockdown inhibits MM cell viability. Novel, oral, irreversible selective inhibitors… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 90 CITATIONS, ESTIMATED 75% COVERAGE

FILTER CITATIONS BY YEAR

2013
2019

CITATION STATISTICS

  • 15 Highly Influenced Citations

  • Averaged 9 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 48 REFERENCES

Aurora A kinase

Y Yao, Y Dong, +3 authors P Chen
  • J Biol Chem
  • 2012